Select Location
What is your delivery location?
We need your delivery location to continue browsing
Select Location
We need your delivery location to continue browsing
Prescription Required
Natco
28 Tablet
Regorafenib
Keep in cold place
Delivering To:
Overview
Regonat 40mg Tablet belongs to the category of anticancer medicines. These medicines are primarily used to treat patients diagnosed with colon and rectum cancer. The growth of cancer cells is uncontrollable and abnormal in the human body. It is difficult to diagnose cancer in the early stages. When diagnosed in advanced stages, only the symptoms of the disease can be reduced. Regonat Tablet is usually given in combination with another anticancer medicine as a part of combination therapy to increase the efficacy of the treatment.
Rectal Cancer, Colorectal Cancer
Regonat 40 mg tablet is used in the treatment of:
1. Colorectal cancer has started to spread to other parts of the body
2. Gastrointestinal stromal tumors (GIST) (a type of stomach and bowel cancer)
3. Liver cancer in adult patients who have already undergone treatment with Sorafenib
The human body shows undesired symptoms after taking Regonat 40mg Tablet. Usually, they disappear with time as the body adjusts to the medicine. These side effects don't need special medical attention. It is advised to consult your doctor if these symptoms become unmanageable.
Some of the common side effects of Regonat Tablet are mentioned below:
Rash
Fever
Hair loss
Diarrhea
Infection
Body pain
Weakness
Headache
Weight loss Low appetite
Changed voice
Low blood count
Nausea & Vomiting
High Blood pressure
Infection of the stomach
Inflammation of the mouth
Unusual bleeding and bruising
Increased level of liver enzymes
Low levels of platelets and WBCs, Severe side effects
Chest pain
Thyroid problem
Bilirubin in urine
Skin detachment
Secondary cancer
Severe allergic reactions
High level of uric acid in the blood
Regonat 40mg Tablet is a prescription-based anticancer drug that should be administered orally. It is advised to take this tablet after consulting your healthcare expert.
Regonat 40mg Tablet is an anticancer medicine that belongs to the drug class of Tyrosine kinase inhibitors. This drug inhibits the formation of blood vessels that are responsible for the blood supply to the tumor cells. That’s how it slows down and stops the growth of cancer cells and also prevents their spread to nearby organs.
Alcohol
consult your doctor
The interaction of alcohol with this drug is still unknown. It is advisable not to consume alcohol while taking Regonat 40mg Tablet. It is advised to consult your doctor for further information.
Pregnancy
consult your doctor
Regonat 40mg Tablet may be considered unsafe during pregnancy. Please consult your doctor in such condition.
Breast Feeding
consult your doctor
Regonat 40mg Tablet is probably not safe if you're breastfeeding. Kindly consult your doctor.
Driving
unsafe
It is advisable not to drive or operate heavy machinery as you may feel dizzy after taking Regonat 40mg Tablet.
Kidney
safe if prescribed
Share your medical history with your healthcare expert in case of kidney disease before taking Regonat 40mg Tablet.
Liver
safe if prescribed
Inform your doctor before starting Regonat 40mg Tablet if you have liver disease to avoid any serious side effects.
It is advised not to miss any scheduled dosage of Regonat 40mg Tablet. In case you miss a dose, consult your doctor immediately.
Don't overdose to compensate for the missed one. Contact your doctor or any healthcare provider and seek medical attention immediately in such cases.
It is advised to use effective birth control ways and avoid pregnancy during the treatment with Regonat 40mg Tablet.
A person should avoid smoking while undergoing treatment with Regonat 40mg Tablet. Smoking may reduce the effectiveness of medicine.
Monitor your blood sugar & pressure, Kidney & Liver function (KFT & LFT), Heart function at proper intervals after taking Regonat 40mg Tablet.
Skin becomes extremely sensitive after taking Regonat 40mg Tablet. It is advised to cover your skin exposed to direct sun rays and use high SPF sunscreen before going out.
It is advised to avoid taking analgesics/ antacids (medicines used to neutralize the stomach acid) while taking Regonat 40mg Tablet, as it may reduce the effectiveness of the medicine.
Keep your body hydrated as Diarrhea is one of the common side effects experienced after taking Regonat 40mg Tablet. Consult your doctor if it doesn't stop or if blood appears in your stools.
If you experience any kind of symptoms after taking Regonat 40mg Tablet like unexplained bruising or bleeding, sore throat, mouth ulcers, high temperature (fever), or other signs of infection, it is important to Inform your doctor as soon as possible.
This medicine is given to adults diagnosed with Colorectal cancer, Gastrointestinal stromal tumors, and Liver cancer.
Regonat Tablet is taken orally with or without food as per the doctor's advice. It is consumed at the same time each day for better results. It is recommended not to crush, chew, or split the capsules; take them as a whole.
The most common side effects of this medicine include Diarrhea, Headache, Tiredness, Mouth sores, Muscle or joint pain, Stomach pain, and difficulty breathing. It is advised to go for regular liver function tests to examine the liver function.
People diagnosed with severe liver and kidney disorders are advised to consult their healthcare professionals before taking this medicine.
Yes, regonat is given alone or in combination with other medicines to treat other cancer or to increase treatment effectiveness.
When other drugs and therapies fail to treat stomach, colon, or rectal cancer, Regonat 40 mg tablets are used as chemotherapy.
No, because grapefruit juice reduces the medication's effectiveness, patients are recommended not to consume it while taking this medication.
Due to its adverse impacts on the developing baby, this medicine should not be used by anybody who is planning to become pregnant or who is already pregnant.
At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.
Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.
Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.
We currently ship to:
Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!
Finn RS, Iyer R, Kalman RS, Parikh ND, Cabrera R, Babajanyan S, Kaseb AO. (2025) Tolerability and Effectiveness of Regorafenib Treatment in Patients with Unresectable Hepatocellular Carcinoma: Real-World Data from the United States. J Hepatocell Carcinoma. 12:231-246.
Han, Y., Xie, J., Wang, Y. et al. (2025) Efficacy and safety of regorafenib in the treatment of bone sarcomas: systematic review and meta-analysis. BMC Cancer 25(1), 302.
Kensei Yamaguchi, Yoshito Komatsu, Taroh Satoh, Hiroyuki Uetake, Takayuki Yoshino, Toshirou Nishida, Naoya Yamazaki, Hajime Takikawa, Takashi Morimoto, Masayuki Chosa, Toshiyuki Sunaya, Yoko Hamada, Kei Muro, Kenichi Sugihara, Large‐Scale, Prospective Observational Study of Regorafenib in Japanese Patients with Metastatic Colorectal Cancer in a Real‐World Clinical Setting, The Oncologist, 24 (7), Pages e450-e457.
Kim, R.D. et al. (2025). 83P Real-world (RW) study of metastatic colorectal cancer (mCRC) patients (pts) with long-term response (LTR) to regorafenib (REG) in the USA: An updated analysis. Annals of Oncology, 35(1), S41.
Liu, S., Gao, S., Guo, J., Kou, F., Zhang, X., Liu, B., Feng, A., Wang, X., Chen, H., & Zhu, X. (2023). A real‑world study of transarterial chemoembolization combined with regorafenib ± PD‑1 inhibitors as second‑line treatment for advanced hepatocellular carcinoma. Journal of Clinical Oncology, 41(16_suppl), e16144
Shen, Yunzhi BS, Bai, Yu MS (2025). Effectiveness of regorafenib in second-line therapy for advanced hepatocellular carcinoma: A systematic review and meta-analysis. Medicine 104(4).
Undefined Authors. (2023). Efficacy and safety of radiotherapy combined with regorafenib for advanced hepatocellular carcinoma: A real‑world study. Journal of Clinical Oncology, 41(16_suppl), e16142.
Yisilamu, P., & Ge, Y. (2024). Regorafenib plus for third‑line treatment in metastatic colorectal cancer: A real‑world study. Journal of Clinical Oncology, 42(16_suppl) e15562.
Natco
Written By
Venika Choudhary
Medical Content Writer @ Magicine Pharma
I hold an M.Sc. in Microbiology and have a strong academic foundation in microbial sciences and applied biotechnology. I began my career with extensive hands-on research at CSIR laboratories, focusing on fungal enzyme production, studying fungal diversity in various ecosystems, and developing bio-pesticides as sustainable alternatives to chemical pesticides. This work deepened my understanding of fungal biology, bioactive compounds, and their pharmaceutical and agricultural applications. Transitioning from research, I now work as a medical content writer, where I combine my scientific expertise with a passion for clear and reliable healthcare communication. I apply my research background to create patient-friendly, compliant content for pharmaceutical companies and healthcare platforms, ensuring science is both trustworthy and accessible. Specializing in clear, accurate, and engaging content, I help patients make informed decisions and support pharmaceutical companies in delivering trusted information. Whether writing product descriptions, crafting disease awareness articles, or composing drug information leaflets, I consistently meet regulatory standards and address audience needs, making my content an asset for healthcare brands.
Reviewed By
Dr. Aditya Sarin - MBBS, MD, DrNB - Consultant Medical Oncology
Dr. Aditya Sarin, MBBS, MD, DrNB, is a highly qualified medical oncologist with profound research and clinical expertise, currently working at Sir Ganga Ram Hospital, New Delhi. He is also a member of the European Society of Medical Oncology (ESMO), a non-profit European organization dedicated to eradicating cancer by promoting comprehensive cancer care and advancing medical oncology. He has been honored with several awards, including the International Cancer Foundation scholarship (ESMO congress, 2022) and Young Medical Oncologist of the Year (Times of India, 2024). He is well-known for his breakthrough in oncology. Dr. Sarin is passionate about converting complex health information into a concise and clear form that is understandable to everyone, aiming to create awareness and cancer care among people.